Haese, Alexander
Tin, Amy L.
Carlsson, Sigrid V.
Sjoberg, Daniel D.
Pehrke, Dirk
Steuber, Thomas
Huland, Hartwig
Graefen, Markus
Scardino, Peter T.
Schlomm, Thorsten
Vickers, Andrew J.
Lilja, Hans
Sauter, Guido
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, P50 CA092629)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
DH | National Institute for Health Research
Cancerfonden (CAN 2017/559)
VetenskapsrÄdet ((VR-MH project no. 2016-02974)
Article History
Received: 13 January 2020
Revised: 17 April 2020
Accepted: 6 May 2020
First Online: 29 May 2020
Ethics approval and consent to participate
: Ethical approval was obtained from the MSKCC IRB. Consent was not sought from participants for this retrospective biomarker study as this was waived by the IRB. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: The data sets analysed for this study will be made available to researchers on reasonable request to the corresponding author.
: Hans Lilja holds patents on assays for free PSA, intact PSA and hK2. Andrew Vickers, Hans Lilja, and Peter Scardino are named on a patent for a statistical method to detect prostate cancer (the 4KScore test) that has been commercialised by OPKO Health. Andrew Vickers, Hans Lilja and Peter Scardino receive royalties from sales of the test. Hans Lilja and Peter Scardino have stock, and Andrew Vickers has stock options in OPKO Health. Sigrid Carlsson has received a lecture honorarium and travel support from Astellas Pharma (unrelated to the current study). The other authors declare no other competing interests.
: This work was supported in part by the National Institutes of Health/National Cancer Institute (NIH/NCI) with a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center [P30 CA008748], a SPORE grant in Prostate Cancer to Dr. H. Scher [P50 CA092629], the Sidney Kimmel Center for Prostate and Urologic Cancers, David H. Koch through the Prostate Cancer Foundation. This work was also supported in part by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Program in the United Kingdom, the Swedish Cancer Society (CAN 2017/559), the Swedish Research Council (VR-MH project no. 2016-02974) and General Hospital in Malmö Foundation for Combating Cancer.